NASDAQ : CELUW

Celularity Inc.

$0.0019 USD

$0.0 (533.33%)

Volume
0
Average Volume
40.07K
Market Capitalization
$48.64K
P/E Ratio
-0.19
Dividend Yield
0.00%
Price Target
Year High
$0.03
Year Low
$0.00
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$0.15
Company Overview

NASDAQ

Robert Joseph Hariri

Biotechnology

Healthcare

CELUW

115

US

USD

https://www.celularity.com

908 768 2170

151190113

0001752828

Liquidity Metrics

-1.07

0.15

0.15

0.08

0.00

Sales & Valuation

$26.55M

0.76

-0.47

-1.53

-0.52

Profitability

-$3.59

-$91.8M

-345.44%

-345.44%

411.46%

-85.45%

P/E Metrics

-0.19

0.01

0.01

Analyst Price Target & Rating

N/A

0/5

4 Analysts

%

Financial Health Scores

-15.11

2/9

-$68.44M

$107.33M

$145.39M

-$56.5M

Key Metrics (TTM)

$54.6M

2.06

-0.70

0.15

411.46%

-151.11%

-521.81%

-66.69%

-1419 days

Company Executives
Name Title
Ricardo J. Gonzalez Chief Commercial Officer
Steven N. Gordon Chief Operating and Administrative Officer & Director
Kyle Harold Fletcher Chief Legal and Strategy Officer & Corporate Secretary
Robert Joseph Hariri Founder, Chief Executive Officer & Chairman
Tim Wilk Senior Vice President of Technical Operations
Sharmila Koppisetti Senior Vice President of Clinical Dev. Immunology & Drug Safety
Carlos Ramirez SVP of Investor Relations
David Jakob Lemus Treasurer
John Sprague Acting Chief Financial Officer
Poll Results

No votes yet today — be the first to share your view!

About Celularity Inc. (NASDAQ:CELUW) Stock

Celularity Inc., a biotechnology company actively engaged in clinical trials, specializes in developing "off-the-shelf" allogeneic cell therapies sourced from placentas. These innovative treatments are designed to address a range of serious conditions, including various cancers, immune system dysfunctions, and infectious illnesses. The company's business activities are categorized into three main divisions: Cell Therapy, Degenerative Disease, and BioBanking. Among its leading therapeutic candidates, CYCART-19, a placental-derived CAR-T therapy, is currently in Phase I trials for treating B-cell malignancies. CYNK-001, an unmodified natural killer (NK) cell also derived from placentas, is undergoing Phase I trials for acute myeloid leukemia and a Phase I/IIa trial for glioblastoma multiform ... e and COVID-19. Another investigational therapy, CYNK-101, an allogeneic genetically modified NK cell, is in Phase I for HER2-positive gastric and gastroesophageal cancers. Moreover, two placenta-derived mesenchymal-like adherent stromal cell therapies, APPL-001 (for Crohn's disease) and PDA-002 (for facioscapulohumeral muscular dystrophy), are progressing through pre-clinical development. In addition to its therapeutic pipeline, Celularity sells and licenses products like Biovance and Interfyl, which are utilized in surgical and wound care markets. The company also operates a service under the LifebankUSA brand, focusing on collecting stem cells from umbilical cords and placentas and providing secure storage for these cells. Celularity Inc. was founded in 2016 and maintains its corporate headquarters in Florham Park, New Jersey.

Frequently Asked Questions

What is the current Celularity Inc. (CELUW) stock price?

Celularity Inc.(NASDAQ:CELUW) stock price is $0.0019 in the last trading session. During the trading session, CELUW stock reached the peak price of $0.0252 while $0.0003 was the lowest point it dropped to. The percentage change in CELUW stock occurred in the recent session was 533.33% while the dollar amount for the price change in CELUW stock was $0.0.

CELUW's industry and sector of operation?

The NASDAQ listed CELUW is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of CELUW?

Ricardo J. Gonzalez | Chief Commercial Officer
Steven N. Gordon | Chief Operating and Administrative Officer & Director
Kyle Harold Fletcher | Chief Legal and Strategy Officer & Corporate Secretary
Robert Joseph Hariri | Founder, Chief Executive Officer & Chairman
Tim Wilk | Senior Vice President of Technical Operations

How many employees does CELUW have?

Number of CELUW employees currently stands at 115. CELUW operates from 170 Park Avenue, Florham Park, NJ 07932, US.

Link for CELUW official website?

Official Website of CELUW is: https://www.celularity.com

How do I contact CELUW?

CELUW could be contacted at phone #908 768 2170 and can also be accessed through its website. CELUW operates from 170 Park Avenue, Florham Park, NJ 07932, US.

How many shares of CELUW are traded daily?

The average number of CELUW shares traded daily for last 3 months was 40.07K.

What is the market cap of CELUW currently?

The market value of CELUW currently stands at $48.64K with its latest stock price at $0.0019